US Food and Drug Administration approval of Lumicell Inc.’s optical imaging agent Lumisight (pegulicianine) brought the number of novel imaging agents to clear the agency’s Center for Drug Evaluation and Research to 14 since 2019, reflecting burgeoning drug development in the long-quiet space.
Lumisight also brought CDER’s count of new molecular entities and novel
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?